A large study from the University of Nottingham has discovered that standard gout medications may significantly reduce the risk of heart attack and stroke in patients with the condition, offering an unexpected cardiovascular benefit beyond relieving joint pain.
The research, published in JAMA Internal Medicine, examined nearly 110,000 gout patients over five years and found that those who lowered their blood urate levels to target thresholds had substantially better outcomes. The work involved researchers from universities across the UK, Sweden, and Italy.
Gout affects roughly one in 40 adults in the UK and EU and occurs when excess urate in the blood forms sharp crystals in joints, triggering sudden episodes of severe pain and swelling. While the condition has long been associated with higher cardiovascular disease risk, the new evidence suggests treating it aggressively may protect the heart as well as the joints.
The study focused on allopurinol and similar urate-lowering drugs, medications already prescribed widely to manage gout flares. The key finding centered on whether achieving a specific urate target, below 360 micromol/L, would translate to fewer heart attacks and strokes.
Researchers divided patients into two groups. One reached the target urate level within 12 months of starting treatment, while the other did not. Over the next five years, those who hit the target showed significantly higher survival rates and a lower risk of major cardiovascular events like heart attack, stroke, or cardiovascular death.
The protective effect was even more pronounced in patients already at high or very high cardiovascular risk. Those who achieved an even lower urate level, below 300 micromol/L, saw greater reductions in risk. The same patients also experienced fewer gout attacks overall.
Professor Abhishek, who led the research at Nottingham, emphasized that the dosing matters. "The right dose varies from person to person and is the dose that gets the blood urate level to less than 360 micromol/L," he said. "This is the first study to find that medicines such as allopurinol used to treat gout reduce the risk of heart attack and stroke if they are taken at the right dose."
The study relied on an innovative approach called an emulated target trial, which analyzed existing healthcare data from primary care records linked to hospital and mortality records between 2007 and 2021. This method allowed researchers to assess outcomes efficiently without conducting a traditional randomized trial.
The dual benefit of properly managing gout offers patients a powerful incentive to stick with urate-lowering treatment. Beyond preventing the painful joint symptoms that define gout, reaching recommended urate targets appears to meaningfully protect against serious cardiovascular events.
Author Jessica Williams: "This flips the script on gout treatment from a quality-of-life issue to a genuine cardiovascular intervention, which could reshape how doctors and patients think about staying compliant with these medications."
Comments